State Street Corp Acquires 58,698 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

State Street Corp raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 9.1% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 703,843 shares of the specialty pharmaceutical company’s stock after acquiring an additional 58,698 shares during the period. State Street Corp owned approximately 3.35% of ANI Pharmaceuticals worth $41,991,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of ANIP. Stifel Financial Corp bought a new position in ANI Pharmaceuticals in the third quarter worth approximately $418,000. Janus Henderson Group PLC raised its stake in shares of ANI Pharmaceuticals by 83.7% in the third quarter. Janus Henderson Group PLC now owns 9,510 shares of the specialty pharmaceutical company’s stock worth $568,000 after purchasing an additional 4,333 shares during the last quarter. Hotchkis & Wiley Capital Management LLC acquired a new stake in shares of ANI Pharmaceuticals in the third quarter worth $3,107,000. HighTower Advisors LLC purchased a new stake in shares of ANI Pharmaceuticals in the third quarter worth about $222,000. Finally, Martingale Asset Management L P grew its position in ANI Pharmaceuticals by 65.3% during the third quarter. Martingale Asset Management L P now owns 34,740 shares of the specialty pharmaceutical company’s stock valued at $2,073,000 after buying an additional 13,719 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at approximately $2,943,540. This represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,231 shares of company stock valued at $2,434,286. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $53.35 on Friday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock’s 50 day moving average is $57.93 and its two-hundred day moving average is $60.09. ANI Pharmaceuticals, Inc. has a twelve month low of $52.00 and a twelve month high of $70.81. The firm has a market capitalization of $1.12 billion, a PE ratio of -97.00 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. The business had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.05 EPS. Research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Leerink Partners started coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. HC Wainwright reaffirmed a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, Raymond James raised their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.